Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patient and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of informatic unless it contains a valid OMB control number
Substitute for form 1449AIPTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Complete If Known

 Application Number
 10/526,768

 Filing Date
 NOVEMBER 7, 2005

 First Named Inventor
 Enno KLUSSMAN et al.

 Group Art Unit
 1652

 Examinor Name
 SWOPE, Sheridan PhD

 Attorney Docken Number
 HERTIN-0001

(use as many sheets as necessary)
Sheet 1 of

U.S. PATENT DOCUMENTS						
	Cite No.1	U.S. Patent Docu			Date of Publication of Cited Document	
Examiner Initials *		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY	

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document			Date of Publication of Where Releva			
Examiner Initials*	Cite No.1	Office ³	Number ⁴	(if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T*
	01	WO	99/62933	A1	Wallukat et al.	12-09-1999		
	02	wo	02/38592	A2	Egner et al.	05-16-2002		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{**}Linique distallor designation number.** See attached Kinds of U.S. Patent Documents.** Enter Office that issued the document, by the two-letter code of WIPO Standard ST3.** For Jupanese potent documents, be indication of the year of the reign of the Empore must proceed the sair interpretation of the Coursent.** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible *Applicant is to place a check mark here it English imaguage Translation is attached. Number refers to English imaguage corresponding family member.**

Buden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case Any comments or the amount of time you are required to complete this form should be sent to the folder information Office, U.S. Patient and Trademark. Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patients, P.O. Sox 1459, Newardria, Var.2313-1400.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Oraci i ici i aporni	ATT FEAT	coorrect or 1000, no person a u	C roquired to respond to a concentrario	Montalon di locario di la la valla civio constanta la la	
Substitu	te for form 1449A/PT0)		Complete if Known		
INIT	DMATION	DIC	CLOSURE	Application Number	10/526,768	
				Filing Date	NOVEMBER 7, 2005	
STA	TEMENT B	ΥA	PPLICANT	First Named Inventor	Enno KLUSSMAN et al.	
				Group Art Unit	1652	
	(use as many she	ets as	necessary)	Examiner Name	SWOPE, Sheridan PhD	
Sheet	2	of	2	Attorney Docket Number	HERTIN-0001	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, oity and/or country where published	T 2		
	003	KLUSSMAN ET AL. "An inhibitory role of Rho in vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells." ABSTRACT ONLY.			
	004	SCHNEIDER ET AL. "Peptide design by artificial neural networks and computer-based evolutionary search." <i>Proc. Natl. Acad. Sci. USA</i> Vol. 95, pp. 12179–12184, October 1998			
	006	HUNDSRUCKER ET AL. "High-affinity AKAP7d-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides." <i>Blochem. J.</i> , 396, 297–306, 2006.			

Examiner	Date
Signature	Considered

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Buden New Statement: This form is estimated to take 2.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the anount of time you are required to complete hits form sould use sent to the Cyte information CHoice, U.S. Patient and Tademark. Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patients, P.O. BOX 1450. Alexandria, VA 20231-1450.